In line with our study, a loss of METTL3 or METTL14 in CRC was reported to promote IFN-γ-Stat1-Irf1-signaling in an m6A-dependent manner to regulate anti-tumor immune responses upon anti-PD-1 therapy [78]. Here, METTL3 is linked to neoplasm.